28 Aug 2018 17:40
SalvaRx Group plc
("SalvaRx" or the "Company")
Update re proposed disposal and demerger
Further to the announcement of 14 August 2018 relating to the proposed disposal of the Company's 94.2 per cent. interest in its subsidiary SalvaRx Limited to Portage Biotech Inc. ("Portage"), the Company has been informed that the Portage shareholder circular has now been submitted to the Canadian Securities Exchange ("CSE") for review. Following completion of the CSE review, both Portage and the Company will publish their respective shareholder circulars and a further announcement will be made by the Company.
Enquiries
SalvaRx Group plc |
|
Ian B. Walters, MD (Chief Executive) | Tel: +1 203 441 5451 |
Northland Capital Partners Limited Nominated Adviser and Broker | Tel: +44 (0) 20 3861 6625
|
Matthew Johnson / Edward Hutton (Corporate Finance) | |
Vadim Alexandre (Corporate Broking) |
SALV.L (SALV)